Merck KGaA is spreading its bets on an artificial-intelligence-enabled future for drug discovery, inking similar three-target deals with BenevolentAI and Exscientia. The deals are collectively worth more than $30 million upfront and $1 billion in potential milestones.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,